Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 23:8:800945.
doi: 10.3389/fmolb.2021.800945. eCollection 2021.

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer

Dong Chen  1 , Yunlin Ye  1 , Shengjie Guo  1 , Kao Yao  1
Affiliations
Review

Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer

Dong Chen et al. Front Mol Biosci. .

Abstract

Bladder cancer is a lethal malignancy and a majority of bladder cancer arise from urothelial cells. Infiltration and metastasis are barriers for the radical cystectomy to achieve favored outcome and are the main cause of death. Systemic therapy, including chemotherapy, targeted therapy, and immunotherapy, is fundamental for these patients. erbB/HER receptors are found to be overexpressed in a subgroup of urothelial carcinoma, targeting erbB/HER receptors in these patients was found to be an efficient way in the era of genetic testing. To evaluate the role of erbB/HER receptors in bladder cancer, we reviewed the literature and ongoing clinical trials as regards to this topic to unveil the context of erbB/HER receptors in bladder cancer, which probably help to solidate the theoretical basis and might instruct further research.

Keywords: (HER); ErbB (EGFR); bladder cancer (BCa); urothelial carcinoma; urothelial carcinoma (UC).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Barnes N. L. P., Khavari S., Boland G. P., Cramer A., Knox W. F., Bundred N. J. (2005). Absence of HER4 Expression Predicts Recurrence of Ductal Carcinoma In Situ of the Breast. Clin. Cancer Res. 11 (6), 2163–2168. 10.1158/1078-0432.ccr-04-1633 - DOI - PubMed
    1. Bryan R. T., Regan H. L., Pirrie S. J., Devall A. J., Cheng K. K., Zeegers M. P., et al. (2015). Protein Shedding in Urothelial Bladder Cancer: Prognostic Implications of Soluble Urinary EGFR and EpCAM. Br. J. Cancer 112 (6), 1052–1058. 10.1038/bjc.2015.21 - DOI - PMC - PubMed
    1. Carlsson J., Wester K., De La Torre M., Malmström P.-U., Gårdmark T. (2015). EGFR-expression in Primary Urinary Bladder Cancer and Corresponding Metastases and the Relation to HER2-Expression. On the Possibility to Target These Receptors with Radionuclides. Radiol. Oncol. 49 (1), 50–58. 10.2478/raon-2014-0015 - DOI - PMC - PubMed
    1. Daizumoto K., Yoshimaru T., Matsushita Y., Fukawa T., Uehara H., Ono M., et al. (2018). A DDX31/Mutant-P53/EGFR Axis Promotes Multistep Progression of Muscle-Invasive Bladder Cancer. Cancer Res. 78 (9), 2233–2247. 10.1158/0008-5472.can-17-2528 - DOI - PubMed
    1. de Martino M., Zhuang D., Klatte T., Rieken M., Rouprêt M., Xylinas E., et al. (2014). Impact ofERBB2mutations on In Vitro Sensitivity of Bladder Cancer to Lapatinib. Cancer Biol. Ther. 15 (9), 1239–1247. 10.4161/cbt.29687 - DOI - PMC - PubMed